Opinion|Videos|February 20, 2025
Step Edits Associated with IV Iron Therapies
Panelists discuss how increasing insurance step edit requirements for high-dose IV iron formulations have created barriers to optimal patient care, requiring providers to implement strategic prior authorization processes and develop documentation protocols to demonstrate medical necessity while advocating for appropriate patient access to these medications.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How has the recent increase in step edits for high-dose IV iron injections impacted your practice?
- How can providers still ensure access to high-dose IV iron formulations?
Advertisement
Related to this article
At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Advertisement
Advertisement
Trending on AJMC
1
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
2
Medicare Plan Terminations Hit 4.3 Million as Part D Market Shrinks
3
Menin Inhibitors in AML: In NYC, Experts Map the Path From Academic Centers to Community Care
4
Youths With Depression Face Higher Odds of Prescription Drug Misuse
5